Scaling Next-Gen MSC Therapies Without Scaling Risk

Mesenchymal stromal cell (MSC) therapies are entering a pivotal stage of development. As more programs move toward late-stage clinical trials and commercialization, developers must produce enough high-quality cells to meet growing demand while maintaining potency, consistency, and manufacturability. How can companies scale MSC production without compromising the biological properties that drive therapeutic efficacy?

Join Cell & Gene’s Chief Editor, Erin Harris, for this Cell & Gene Live discussion featuring Miguel Forte, M.D., Ph.D., CEO of Kiji Therapeutics, Silviu Itescu, M.D., Founder, CEO, and Managing Director of Mesoblast, and Edward Ahn, Ph.D., CEO of MEDIPOST. Together, these experts bring decades of experience developing, manufacturing, and commercializing MSC therapies. Their combined expertise spans early innovation, scalable manufacturing, and commercial execution.

The expert panel will discuss strategies for scaling MSC therapies while minimizing donor variability, preserving potency, improving process consistency, and building commercially viable manufacturing platforms. They will also examine advances in cell sourcing, process development, quality systems, and manufacturing strategy. Attendees will leave with practical insights into what developers should prioritize today to improve their products’ chances of clinical and commercial success.

Registration is free.